Pulmatrix Reports Q1 Results, Confirms Eos SENOLYTIX Merger On Track

summarizeSummary

Pulmatrix reported Q1 financials with a reduced net loss and confirmed its cash runway extends through the planned merger with Eos SENOLYTIX, a critical strategic transaction.

check_boxKey Events

• Q1 2026 Financial Results

  Reported a net loss of $1.172 million for the first quarter, an improvement from $1.808 million in Q1 2025. Research and development expenses were less than $0.1 million.

• Cash Position and Runway

  Ended Q1 2026 with $3.3 million in cash and cash equivalents. The company anticipates this cash position is sufficient to fund operations at least through the anticipated Q3 2026 closing of the proposed merger with Eos SENOLYTIX.

• Eos SENOLYTIX Merger Confirmed

  Reaffirmed the definitive merger agreement with Eos SENOLYTIX, expected to close in the third quarter of 2026. This merger will transform Pulmatrix into a gerotherapeutic company.

• Asset Monetization Strategy

  Pulmatrix is actively seeking to out-license or monetize its iSPERSE™ technology and clinical assets, including PUR1900 (advancing to Phase 3 in India), PUR3100 (Phase 2-ready), and PUR1800.

auto_awesomeAnalysis

Pulmatrix provided its first-quarter financial results, showing a reduced net loss and a cash position of $3.3 million. Crucially, the company confirmed its cash runway is sufficient through the anticipated closing of the definitive merger agreement with Eos SENOLYTIX in Q3 2026. This update is important as it provides financial clarity and reaffirms the strategic pivot following the termination of a previous merger, offering a path forward for the micro-cap company.